I. Simone

Withdrawal of mechanical ventilation in amyotrophic lateral sclerosis patients: a multicenter Italian survey
20232 citationsauthor #58
Clinical Profiles and Patterns of Neurodegeneration in Amyotrophic Lateral Sclerosis: A Cluster-Based Approach Based on MR Imaging Metrics
20235 citationsauthor #8
The HFE p.H63D (p.His63Asp) Polymorphism Is a Modifier of ALS Outcome in Italian and French Patients with SOD1 Mutations
20234 citationsauthor #12
Acoustic Voice Analysis as a Useful Tool to Discriminate Different ALS Phenotypes
202311 citationsauthor #10
Adults with spinal muscular atrophy: a large-scale natural history study shows gender effect on disease
202215 citationsauthor #42
Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double‐blind, placebo‐controlled trial
202221 citationsauthor #42
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies
202225 citationsauthor #23
Medulla oblongata volume as a promising predictor of survival in amyotrophic lateral sclerosis
202210 citationsauthor #8
Individual Oligogenic Background in p.D91A-SOD1 Amyotrophic Lateral Sclerosis Patients
20216 citationsauthor #4
Reduction of Sniff Nasal Inspiratory Pressure (SNIP) as an Early Indicator of the Need of Enteral Nutrition in Patients with Amyotrophic Lateral Sclerosis
20213 citationsauthor #8
King's college progression rate at first clinical evaluation: A new measure of disease progression in amyotrophic lateral sclerosis.
20215 citationsauthor #8
The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial
202148 citationsauthor #21
Subclinical upper motor neuron involvement at the diagnosis may predict disease progression in a cohort of lower motor neuron syndromes from Southern Italy.
20215 citationsauthor #8
Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone
20218 citationsauthor #9
King's progression rate: Prognostic value in amyotrophic lateral sclerosis according to cerebrospinal neurofilament light chain levels
20210 citationsauthor #9
Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies
202128 citationsauthor #1
Cerebrospinal Fluid and Clinical Profiles in Adult Type 2–3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience
202117 citationsauthor #12
Medulla oblongata volume predicts survival in amyotrophic lateral sclerosis patients
20210 citationsauthor #9
Is cerebrospinal fluid amyloid‐β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients?
202116 citationsauthor #8
Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy
202116 citationsauthor #6
6MWT as measure of motor function and endurance in SMA type 3 patients treated with nusinersen
20210 citationsauthor #38
The importance of maintaining the same order of performance of lung function and SNIP tests in patients with amyotrophic lateral sclerosis
20204 citationsauthor #11
Inclusion of motor evoked abnormalities in amyotrophic lateral sclerosis: a diagnostic algorithm to early classify lower motor neuron phenotypes
20201 citationsauthor #9
Motor-evoked potentials in amyotrophic lateral sclerosis: potential implications in detecting subclinical UMN involvement in lower motor neuron phenotype
202018 citationsauthor #11
A 71‐nucleotide deletion in the periaxin gene in an Italian patient with late‐onset slowly progressive demyelinating Charcot‐Marie‐Tooth disease
20200 citationsauthor #4
The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis
202057 citationsauthor #11
Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3
2020139 citationsauthor #38
Genetic investigation of amyotrophic lateral sclerosis patients in south Italy: a two-decade analysis.
202021 citationsauthor #6
G-CSF(filgrastim)treatmentfor amyotrophiclateralsclerosis:protocol foraphaseIIrandomised,double-blind, placebo-controlled,parallelgroup, multicentreclinicalstudy(STEMALS- IItrial)
20209 citationsauthor #10
Nutritional prognostic factors for survival in amyotrophic lateral sclerosis patients undergone percutaneous endoscopic gastrostomy placement
201916 citationsauthor #8
Episodic memory and learning rates in amyotrophic lateral sclerosis without dementia.
201911 citationsauthor #11
Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis
2019131 citationsauthor #79
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.
2019647 citationsauthor #59
Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS)
201951 citationsauthor #14
Convexal subarachnoid hemorrhage and acute ischemic stroke: a border zone matter?
201912 citationsauthor #8
Corrigendum: Dysregulation of MicroRNAs and Target Genes Networks in Peripheral Blood of Patients With Sporadic Amyotrophic Lateral Sclerosis
201824 citationsauthor #9
Dysregulation of MicroRNAs and Target Genes Networks in Peripheral Blood of Patients With Sporadic Amyotrophic Lateral Sclerosis
2018113 citationsauthor #9
Genome-wide Analyses Identify KIF5A as a Novel ALS Gene in and for Therapeutic
2018362 citationsauthor #205
Genome-wide Analyses Identify KIF5A as a Novel ALS Gene in and for Therapeutic
2018362 citationsauthor #38
Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis
201843 citationsauthor #12
MR evaluation of encephalic leukoaraiosis in sudden sensorineural hearing loss (SSNHL) patients
201811 citationsauthor #5
Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial)
201724 citationsauthor #24
Autoimmune epilepsy: Clinical and MRI features in a Southern Italy case series
20170 citationsauthor #7
Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study
201714 citationsauthor #9
The role of imaging in Hirayama disease
20164 citationsauthor #2
Pediatric multiple sclerosis
201678 citationsauthor #4
A rare association between multiple sclerosis and Charcot‐Marie‐Tooth type 1B
20163 citationsauthor #7
ATNX2 is not a regulatory gene in Italian amyotrophic lateral sclerosis patients with C9ORF72 GGGGCC expansion.
201613 citationsauthor #15
TBK1 is associated with ALS and ALS-FTD in Sardinian patients.
201653 citationsauthor #33
The Central Vein Sign on SWI at 3T MRI Differentiates Multiple Sclerosis from Neuromyelitis Optica (P4.147)
20162 citationsauthor #8
Pseudobulbar Affect (PBA) as a Predictor of Survival in ALS (P5.089)
20160 citationsauthor #7
Magnetic Resonance Measures of Subcortical and Cortical Gray Matter in Amyotrophic Lateral Sclerosis (P4.096)
20160 citationsauthor #10
Pseudobulbar affect (PBA) in an incident ALS cohort: results from the Apulia registry (SLAP)
201621 citationsauthor #11
No Differences in Spinal Cord White and Grey Matter Diffusion Abnormalities between Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis (P4.151)
20161 citationsauthor #9
No differences in spinal cord DTI abnormalilties between neuromyelitis optica spectrum disorder and multiple sclerosis
20160 citationsauthor #8
Time to generalization and prediction of survival in patients with amyotrophic lateral sclerosis: a retrospective observational study
201619 citationsauthor #12
Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis
201568 citationsauthor #12
HFE p.H63D polymorphism does not influence ALS phenotype and survival.
201512 citationsauthor #15
Lesion Load May Predict Long-Term Cognitive Dysfunction in Multiple Sclerosis Patients
201538 citationsauthor #20
HFE p.His63Asp polymorphism is not a modifier of ALS phenotype (P2.049)
20150 citationsauthor #19
A Novel CSF1R Mutation in a Patient with Clinical and Neuroradiological Features of Hereditary Diffuse Leukoencephalopathy with Axonal Spheroids
201516 citationsauthor #9
CHCH10 mutations in an Italian cohort of familial and sporadic amyotrophic lateral sclerosis patients.
201550 citationsauthor #14
Vitamin D Levels in Serum of Amyotrophic Lateral Sclerosis Patients. (P2.069)
20155 citationsauthor #9
Time to generalisation as a predictor of prognosis in amyotrophic lateral sclerosis
201520 citationsauthor #8
Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis
201563 citationsauthor #11
Are CSF Tau And Phospho Tau Levels Really Biomarkers Of Amyotrophic Lateral Sclerosis? (P6.003)
20150 citationsauthor #7
Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study
201535 citationsauthor #83
CHCH10 mutations in an Italian cohort of familial and sporadic ALS patients
20150 citationsauthor #14
Assisting persons with advanced amyotrophic lateral sclerosis in their leisure engagement and communication needs with a basic technology-aided program
201515 citationsauthor #2
Hirayama disease: the importance of an early diagnosis
201514 citationsauthor #5
CHCHD10 gene mutations in ALS patients of Italian ancestry (P2.052)
20150 citationsauthor #18
Abnormal White Matter Fraction Predicts Cognitive Dysfunction in Multiple Sclerosis Patients (P6.121)
20140 citationsauthor #19
Genetic Epidemiology of C9ORF72 in ALS: A National Study in Italy (P7.005)
20140 citationsauthor #14
Time To Generalization As A Predictor Of Prognosis In ALS. (P4.095)
20140 citationsauthor #7
Elective Tracheostomy in Amyotrophic Lateral Sclerosis (ALS): The Prognostic Role of Sniff Nasal Ispiratory Pressure (SNIP) (P07.082)
20131 citationsauthor #8
Cortical Thinning and Clinical Heterogeneity in Amyotrophic Lateral Sclerosis
201387 citationsauthor #11
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS
201375 citationsauthor #20
Amyotrophic lateral sclerosis: a new missense mutation in the SOD1 gene
201330 citationsauthor #11
Pseudobulbar Affect (PBA) in an Incident ALS Cohort: Results from the Apulia Registry (P07.073)
20130 citationsauthor #8
Mitochondrial genome aberrations in skeletal muscle of patients with motor neuron disease
201318 citationsauthor #8
MRI and Clinical Predictors in Multiple Sclerosis: 9 Year Follow-Up Study (S10.006)
20130 citationsauthor #3
C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population.
201293 citationsauthor #17
Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis
201281 citationsauthor #7
Verbal Learning Abilities in ALS Patients (P01.109)
20120 citationsauthor #8
Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72.
2012208 citationsauthor #31
Cortical Thinning in Frontal Lobes Is Relate with Faster Progression of Amyotrophic Lateral Sclerosis (P03.161)
20120 citationsauthor #1
Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression
2012143 citationsauthor #12
FUS mutations in sporadic amyotrophic lateral sclerosis: clinical and genetic analysis.
201241 citationsauthor #6
Is Frontal Assessment Battery a Useful Instrument To Detect Cognitive Impairment in ALS
20110 citationsauthor #9
Serum N-acetylaspartate level in amyotrophic lateral sclerosis.
201122 citationsauthor #1
Lower SNIP value is correlated to the need of intubation in amyotrophic lateral sclerosis
20110 citationsauthor #8
Demyelinating Disorders of the Central Nervous System in Childhood: Epidemiology of pediatric multiple sclerosis: incidence, prevalence, and susceptibility risk factors
20110 citationsauthor #3
Homozygous SOD1 D90A Mutation and Cerebellar Involvement in ALS
20110 citationsauthor #9
An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis
201155 citationsauthor #2
N-Acetyl-Aspartate (NAA) and Neurofilament-Light Chain (NF-L) in biological fluids as markers of neurodegeneration in ALS
20110 citationsauthor #1
TARDBP gene mutations in south Italian patients with amyotrophic lateral sclerosis
201037 citationsauthor #3
Laser evoked potentials in amyotrophic lateral sclerosis.
201021 citationsauthor #1
Cerebrospinal fluid and Serum Neurofilament Light Chain Levels in ALS patients.P 02. 239
20100 citationsauthor #1
Lithium carbonate in amyotrophic lateral sclerosis
201095 citationsauthor #23
Real‐life impact of early interferonβ therapy in relapsing multiple sclerosis
2009149 citationsauthor #7

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT